Article: Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab

Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn. She had no personal or family history of psoriasis or chronic inflammatory skin disease. The guttate psoriasis was refractory to topical treatment. After the first dose of guselkumab (100 mg subcutaneous injection), the patient experienced near-clearance of her guttate psoriasis, with continued improvement and drug-free remission 8 months after cessation of treatment. Dermatologists could consider guselkumab as a treatment option for patients with guttate psoriasis. Future studies should examine the potential for guselkumab to induce drug-free remissions in guttate psoriasis.

Citing Articles

Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research.

Gao Y, Xu T, Wang Y, Hu Y, Yin S, Qin Z Pharmaceutics. 2025; 17(1).

PMID: 39861704 PMC: 11769081. DOI: 10.3390/pharmaceutics17010056.

Guselkumab - In Psoriasis and Beyond.

Bubna A, Viplav V Dermatol Pract Concept. 2024; 14(3).

PMID: 39122539 PMC: 11314551. DOI: 10.5826/dpc.1403a181.

Management of Guttate Psoriasis: A Systematic Review.

Zhou T, Koussiouris J, Kim L, Vender R J Cutan Med Surg. 2024; 28(6):577-584.

PMID: 39080843 PMC: 11619194. DOI: 10.1177/12034754241266187.

References

1.

Sofen H, Smith S, Matheson R, Leonardi C, Calderon C, Brodmerkel C . Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014; 133(4):1032-40. DOI: 10.1016/j.jaci.2014.01.025. View

2.

Terui T, Kobayashi S, Okubo Y, Murakami M, Hirose K, Kubo H . Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial. JAMA Dermatol. 2018; 154(3):309-316. PMC: 5885837. DOI: 10.1001/jamadermatol.2017.5937. View

3.

Horner K, Chien A, Edenholm M, Hornung R . Winnie the Pooh and psoriasis too: an isomorphic response of guttate psoriasis in a tattoo. Pediatr Dermatol. 2007; 24(5):E70-2. DOI: 10.1111/j.1525-1470.2007.00445.x. View

4.

Rendon A, Schakel K . Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20(6). PMC: 6471628. DOI: 10.3390/ijms20061475. View

5.

Teunissen M, Yeremenko N, Baeten D, Chielie S, Spuls P, de Rie M . The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol. 2014; 134(12):2898-2907. DOI: 10.1038/jid.2014.261. View

6.

Ruiz-Romeu E, Ferran M, Sagrista M, Gomez J, Gimenez-Arnau A, Herszenyi K . Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis. J Allergy Clin Immunol. 2016; 138(2):491-499.e6. DOI: 10.1016/j.jaci.2016.02.008. View

7.

Schwarz A, Bhardwaj R, Aragane Y, Mahnke K, Riemann H, Metze D . Ultraviolet-B-induced apoptosis of keratinocytes: evidence for partial involvement of tumor necrosis factor-alpha in the formation of sunburn cells. J Invest Dermatol. 1995; 104(6):922-7. DOI: 10.1111/1523-1747.ep12606202. View

8.

Hall S, Haidari W, Feldman S . Resolution of Guttate Psoriasis Plaques After One-time Administration of Guselkumab. J Drugs Dermatol. 2019; 18(8):822-823. View

9.

Brummer G, Hawkes J, Callis Duffin K . Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series. JAAD Case Rep. 2017; 3(5):432-435. PMC: 5594234. DOI: 10.1016/j.jdcr.2017.06.015. View

10.

Flora A, Frew J . A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality. JAAD Case Rep. 2022; 24:82-87. PMC: 9136601. DOI: 10.1016/j.jdcr.2022.04.019. View